FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005556064> ?p ?o ?g. }

• W2005556064 abstract "Objectives To evaluate the immunogenicity of a two-dose schedule of Baxter cell-cultured, non-adjuvanted, whole-virion H1N1 vaccine, and GlaxoSmithKline AS03A-adjuvanted split-virion H1N1 vaccine with respect to the EU Committee for Medicinal Products for Human Use (CHMP) and the US Food and Drug Administration (FDA) licensing criteria. Design An age-stratified, randomised, observer-blind, parallel-group, multicentre controlled trial was carried out in volunteers aged ≥ 18–44, ≥ 45–64 and ≥ 65 years. Setting Three teaching hospitals in the UK (Leicester Royal Infirmary, Leicester; Nottingham City Hospital, Nottingham; and Royal Hallamshire Hospital, Sheffield). Participants Three hundred and forty-seven subjects were identified and randomised to AS03A-adjuvanted split-virion H1N1 vaccine or whole-virion (WV) vaccine in age groups [≥ 18–44 years (n = 140), ≥ 45–64 years (n = 136) and ≥ 65 years (n = 71)]. Interventions Vaccine was administered by intramuscular injection into the deltoid muscle of the non-dominant arm. One hundred and seventy-five randomised subjects were allocated AS03A-adjuvanted split H1N1 vaccine; one hundred and sixty-nine subjects had a second dose of the same vaccine 21 days later. One hundred and seventy-two subjects were allocated WV vaccine; one hundred and seventy-one subjects had a second dose of the same vaccine 21 days later. Serum samples for antibody measurements were collected on days 0 (before the first vaccination), 7, 14, 21 (before the second vaccination), 28, 35, 42 and 180. Subjects were observed for local and systemic reactions for 30 minutes after each injection, and for the next 7 days they recorded, in self-completed diaries, the severity of solicited local (pain, bruising, erythema and swelling) and systemic symptoms (chills, malaise, muscle aches, nausea and headache), oral temperature and use of analgesic medications. Main outcome measures Vaccine immunogenicity using the CHMP and the FDA licensing criteria. Antibody titres were measured using haemagglutination inhibition (HI) and microneutralisation (MN) assays at baseline and 7, 14 and 21 days after each vaccination and at day 180. The three immunogenicity criteria end points were the seroprotection rate, the seroconversion rate and the mean-fold titre elevation. Results Both vaccine doses were given in 340 subjects (98%). Data from 680 (99%) of 687 issued diary cards were returned. Sera were obtained from 340 (98.0%), 333 (96.0%), 341 (98.3%), 331 (95.4%), 329 (94.8%) and 332 (95.7%) subjects on days 7, 14, 21, 28, 35 and 42, respectively. Three hundred and forty-six and 345 subjects were included in the safety and immunogenicity analyses, respectively. Prevaccination antibody was detected by HI (titre ≥ 1 : 8) and MN (titre ≥ 1 : 10) in 14% and 31% of subjects, respectively. Among the 298 (85.9%) subjects without baseline antibody on HI assay, a titre of ≥ 1 : 40 (seroprotection) was achieved after a single dose of AS03A-adjuvanted vaccine and WV vaccine by day 21 in 93.0% and 65.5%, respectively, of subjects between 18 and 44 years, 76.4% and 36.1% of subjects between 45 and 64 years, and 53.1% and 30.0% of subjects ≥ 65 years. Among all 347 subjects, a titre of ≥ 1 : 40 was achieved after a single dose of AS03A-adjuvanted vaccine and WV vaccine by day 21 in 94.0% and 71.4%, respectively, of subjects between 18 and 44 years, 77.3% and 38.8% of subjects between 45 and 64 years, and 51.4% and 32.4% of subjects ≥ 65 years. The age-adjusted odds ratio (OR) for adjuvanted compared with WV vaccine, in terms of seroprotection, was 4.42 [95% confidence interval (CI) 2.63 to 7.44, p < 0.001]. On day 42, among subjects without baseline antibody on HI assay, a titre of ≥ 1 : 40 was achieved after the second dose of AS03A-adjuvanted vaccine and WV vaccine by 100% and 67.9%, respectively, of subjects between 18 and 44 years, 89.3% and 41% of subjects between 45 and 64 years, and 76.5% and 34.5% of subjects ≥ 65 years. Among all 347 subjects, a titre of ≥ 1 : 40 was achieved on day 42 after the second dose of AS03A-adjuvanted vaccine and WV vaccine in 100% and 73.1%, respectively, of subjects between 18 and 44 years, 90.8% and 43.9% of subjects between 45 and 64 years, and 75.7% and 36.4% of subjects ≥ 65 years. The age-adjusted OR for adjuvanted vaccine compared with WV vaccine, in terms of seroprotection, was 11.21 (95% CI 5.80 to 21.64, p < 0.001). Age-related decline in antibody response occurred after both doses of both vaccines. WV vaccine was associated with fewer local and systemic reactions and lower immune responses than was AS03A-adjuvanted vaccine. The most frequent solicited local event was pain, reported by 28% and 76% of subjects after either dose of WV or adjuvanted vaccine, respectively (OR 7.71, 95% CI 4.48 to 13.24, p < 0.0001). The most common systemic event was myalgia, reported by 24% and 49% of subjects after either dose of WV or adjuvanted vaccine (OR 2.99, 95% CI 1.86 to 4.80, p < 0.0001). Conclusions AS03A-adjuvanted 2009 H1N1 vaccine is more immunogenic and provides greater antigen-sparing capacity than WV 2009 H1N1 vaccine. Trial registration Current Controlled Trials ISRCTN92328241. Funding This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 14, No. 55. See the HTA programme website for further project information." @default.
• W2005556064 created "2016-06-24" @default.
• W2005556064 creator A5004828576 @default.
• W2005556064 creator A5011296226 @default.
• W2005556064 creator A5024597692 @default.
• W2005556064 creator A5035431202 @default.
• W2005556064 creator A5044666278 @default.
• W2005556064 creator A5055194670 @default.
• W2005556064 creator A5064889585 @default.
• W2005556064 creator A5068058927 @default.
• W2005556064 creator A5068218550 @default.
• W2005556064 creator A5074820525 @default.
• W2005556064 creator A5090282427 @default.
• W2005556064 date "2010-12-01" @default.
• W2005556064 modified "2023-10-18" @default.
• W2005556064 title "A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart" @default.
• W2005556064 cites W115856346 @default.
• W2005556064 cites W120207188 @default.
• W2005556064 cites W1471337471 @default.
• W2005556064 cites W1481796766 @default.
• W2005556064 cites W1525438580 @default.
• W2005556064 cites W1841616222 @default.
• W2005556064 cites W1857030017 @default.
• W2005556064 cites W1963594199 @default.
• W2005556064 cites W1969471820 @default.
• W2005556064 cites W1979210826 @default.
• W2005556064 cites W1979460690 @default.
• W2005556064 cites W1980344398 @default.
• W2005556064 cites W1987669718 @default.
• W2005556064 cites W1991892174 @default.
• W2005556064 cites W2008610318 @default.
• W2005556064 cites W2009610406 @default.
• W2005556064 cites W2011879952 @default.
• W2005556064 cites W2013112188 @default.
• W2005556064 cites W2016497602 @default.
• W2005556064 cites W2017832395 @default.
• W2005556064 cites W2021481766 @default.
• W2005556064 cites W2024412478 @default.
• W2005556064 cites W2025333144 @default.
• W2005556064 cites W2034112663 @default.
• W2005556064 cites W2034382342 @default.
• W2005556064 cites W2036596307 @default.
• W2005556064 cites W2039583380 @default.
• W2005556064 cites W2041117870 @default.
• W2005556064 cites W2041753380 @default.
• W2005556064 cites W2044756165 @default.
• W2005556064 cites W2045584501 @default.
• W2005556064 cites W2047381054 @default.
• W2005556064 cites W2052168824 @default.
• W2005556064 cites W2056297672 @default.
• W2005556064 cites W2059684539 @default.
• W2005556064 cites W2061682040 @default.
• W2005556064 cites W2061833503 @default.
• W2005556064 cites W2062190875 @default.
• W2005556064 cites W2068553244 @default.
• W2005556064 cites W2068592034 @default.
• W2005556064 cites W2069699462 @default.
• W2005556064 cites W2075877458 @default.
• W2005556064 cites W2079430155 @default.
• W2005556064 cites W2080447498 @default.
• W2005556064 cites W2082647108 @default.
• W2005556064 cites W2085474794 @default.
• W2005556064 cites W2087508560 @default.
• W2005556064 cites W2090326173 @default.
• W2005556064 cites W2095833880 @default.
• W2005556064 cites W2097158347 @default.
• W2005556064 cites W2101877224 @default.
• W2005556064 cites W2103758376 @default.
• W2005556064 cites W2107587363 @default.
• W2005556064 cites W2111299679 @default.
• W2005556064 cites W2111360869 @default.
• W2005556064 cites W2114555019 @default.
• W2005556064 cites W2123599709 @default.
• W2005556064 cites W2127662109 @default.
• W2005556064 cites W2131170401 @default.
• W2005556064 cites W2137909872 @default.
• W2005556064 cites W2144894027 @default.
• W2005556064 cites W2155078816 @default.
• W2005556064 cites W2155467153 @default.
• W2005556064 cites W2155583328 @default.
• W2005556064 cites W2157725602 @default.
• W2005556064 cites W2158066122 @default.
• W2005556064 cites W2158299279 @default.
• W2005556064 cites W2160885155 @default.
• W2005556064 cites W2162080474 @default.
• W2005556064 cites W2164684229 @default.
• W2005556064 cites W2164860726 @default.
• W2005556064 cites W2170155793 @default.
• W2005556064 cites W2312463092 @default.
• W2005556064 cites W2473040680 @default.
• W2005556064 cites W2486289350 @default.
• W2005556064 cites W2508794604 @default.
• W2005556064 cites W326584983 @default.
• W2005556064 cites W56574006 @default.
• W2005556064 cites W1431288172 @default.
• W2005556064 cites W2118340246 @default.
• W2005556064 doi "https://doi.org/10.3310/hta14550-04" @default.
• W2005556064 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21208550" @default.
• W2005556064 hasPublicationYear "2010" @default.
• W2005556064 type Work @default.

• next